Precision Medical Research of Non-immune Fetal Hydrops (NIFH)-From Prenatal Diagnosis to Intrauterine Treatment

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02956564

Enrollment

144

Registered

2016-11-07

Start date

2016-12-31

Completion date

2018-08-31

Last updated

2016-12-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fetal Hydrops

Brief summary

Based on multi-center clinical research resources, a large-scale prospective cohort study will be conduted to make a more accurate diagnosis and intervention plan of Non-immune fetal hydrops (NIFH), and then establish NIFH accurate treatment strategy which is suitable for China's national conditions.

Detailed description

1. Etiological study of Non-immune fetal hydrops(NIFH): 1. Etiological study of NIFH in mid-pregnancy period; 2. Etiological study of NIFH and hygroma colli in first trimester; 3. Value assessment of technology for exome sequencing in diagnosis of NIFH; 2. The accuracy of NIFH intrauterine intervention and its effect assessment: 1. Perinatal outcomes of NIFH ; 2. The effect of intrauterine treatments.

Interventions

PROCEDUREintrauterine intervention

choose different surgeries according to different causes

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 45 Years

Healthy volunteers

Inclusion criteria

* Cases corresponding to diagnosis standards * Willing to accept the regular follow-up

Exclusion criteria

* Immune hydrops fetalis * Multiple pregnancy, except for twin-to-twin transfusion syndrome IV

Design outcomes

Primary

Measure	Time frame
Neonatal mortality	1 year

Secondary

Measure	Time frame
Success rate for the operation	1 week

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026